FIELD: chemistry.
SUBSTANCE: invention relates to a crystalline form A of (R)-methyl-2-(3-aminopiperidin-1-yl)-3-(2-cyanobenzyl)-4-carbonyl-3,4-dihydrothiophene[3,2-d]pyrimidine-6-carboxylic acid of formula I, where the X-ray diffraction pattern (X-ray powder diffraction pattern) of crystalline form A includes the following characteristic absorption peaks, expressed by the distance between the crystal planes d: 8.87 ± 0.2 Å, 14.18 ± 0.2 Å, 20.67 ± 0.2 Å, 25.18 ± 0.2 Å, 28.61 ± 0.2 Å.
As well as to methods of producing and pharmaceutical composition of crystalline form A.
EFFECT: crystalline form A has strong hypoglycemic activity in vivo and is expected to be a novel pharmaceutically active ingredient for treating or preventing type II diabetes and/or complications of type II diabetes.
8 cl, 7 dwg, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| POLYMORPH MALEATE OF DIPEPTIDYL PEPTIDASE INHIBITOR IV (DPPIV) AND A METHOD FOR PRODUCTION THEREOF | 2017 |
|
RU2732577C1 |
| HYDROCHLORIDE FORM OF INHIBITOR OF DIPEPTIDYLPEPTIDASE IV AND METHOD OF PRODUCING SALT FORM | 2017 |
|
RU2734549C2 |
| COMPOUNDS OF THIENYL[3, 2-d]PYRIMIDINE-4-ON, METHOD FOR PRODUCTION, PHARMACEUTICAL COMPOSITIONS AND THEIR APPLICATION | 2012 |
|
RU2624021C2 |
| NOVEL PHARMACEUTICAL USE OF THIENO[3,2-D]PYRIMIDIN-4-ONE COMPOUNDS | 2019 |
|
RU2768828C1 |
| CRYSTALLINE FORM OF ORGANIC COMPOUND | 2009 |
|
RU2572529C2 |
| THERAPEUTIC ANTIDIABETIC AGENT | 2006 |
|
RU2438671C2 |
| 3-{(3R,4R)-4-METHYL-3-[METHYL-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)AMINO]PIPERIDIN-1-YL}-3-OXOPROPIONITRILE MONOCITRATE CRYSTALLINE FORM AND ITS USING | 2002 |
|
RU2315052C2 |
| CRYSTAL FORM α OF COMPOUND OF MONOBENZOATE, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 2015 |
|
RU2677660C2 |
| CRYSTALS OF 3,5-DISUBSTITUTED BENZOLALKYNYL COMPOUND | 2016 |
|
RU2672563C1 |
| THIAZOLOPYRIMIDINONES AS MODULATORS OF NMDA RECEPTOR ACTIVITY | 2014 |
|
RU2703273C2 |
